Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday.

Structure Therapeutics soared to a new 52-week high on Monday after announcing stellar topline results from its ongoing clinical program to test the efficacy of its therapy candidate, aleniglipron, in obese patients with co-morbidity.

At intra-day trading, the stock surged to its highest price of $94.90 before profit-taking persisted and trimmed its gains to end the day just up by 102.49 percent at $69.98 apiece.

This followed news that patients who took a 120mg dose once daily achieved an 11.3 percent weight loss at 36 weeks, while those who took 240mg reduced weight by up to 15.3 percent in the same period.

Aleniglipron demonstrated a tolerability profile consistent with the GLP-1 receptor agonist class and a compelling off-target safety profile.

Following the results, Structure Therapeutics Inc. (NASDAQ:GPCR) expects to move forward with the third phase of the clinical trial in the middle of 2026.

Before the third phase, it plans to sit down with the Food and Drug Administration in the first half of next year to finalize the phase 3 design, which is currently targeted with a starting titration dose of 2.5 mg with the intent to evaluate multiple doses up to 240 mg.

“These findings provide comprehensive information to move into Phase 3 development and reinforce aleniglipron’s potential to become a backbone oral small molecule therapy for obesity—one that is accessible, scalable, and combinable,” said Structure Therapeutics Inc. (NASDAQ:GPCR) CEO Raymond Stevens.

While we acknowledge the potential of GPCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.